VBL Therapeutics Announces Patient Dosing Initiated in Randomized, Controlled and Blinded Trial of VB-111 in Patients with Recurrent Glioblastoma Multiforme

NEXT STORY
Athenex Provides Fourth Quarter and Full Year 2020 Corporate and Financial Update
PREV STORY
COVID-19 Diagnostics Market Size Worth USD 8.04 Billion at 2.7% CAGR; Pharmaceutical Giants Such as Abbott and Roche to Pump More Funds for R&D Activities: Fortune Business Insights™
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

FIT Biotech Oy: FIT Biotech Oy’s Board of Directors has decided on the issue of Convertible Notes and Warrants

FIT Biotech Oy Company release November 12, 2018 at 5:45 PM EET FIT Biotech ...

author_avatar
NASDAQ Market News

CRISPR Therapeutics and Vertex Pharmaceuticals Announce FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX001™ for the Treatment of Severe Hemoglobinopathies

author_avatar
NASDAQ Market News

Onconova Announces Presentations Related to Rigosertib Clinical Studies in Myelodysplastic Syndromes at the 2016 ASH Annual Meeting

--Rigosertib plus Azacitidine Combination Phase 2 Trial Results Featured-- NEWTOWN, Pa., Nov. 04, 2016 ...

author_avatar
NASDAQ Market News